MIST Stock Analysis: Buy, Sell, or Hold?
MIST - Milestone Pharmaceuticals Inc. Common Shares
$1.28
-0.04 (-3.03%)
▼
5d:
-8.57%
30d:
-32.45%
90d:
-22.42%
HOLD
MODERATE Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When MIST Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called MIST this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MIST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MIST shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MIST is currently trading at $1.28, which is considered oversold relative to its 30-day fair value range of $1.44 to $1.89.
Technical Outlook: Technically, MIST is in a downtrend. The price is currently testing key support at $1.27. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: MIST has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.33 (+394.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MIST is in a downtrend. The price is currently testing key support at $1.27. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: MIST has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.33 (+394.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.44 -
$1.89
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading 394.8% below Wall St target ($6.33)
- CAUTION: 5-day price weakness (-8.6%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.44 -
$1.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.27
Resistance Level
$1.54
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.22
Wall Street Target
$6.33
(+394.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: June 04, 2026 1:57 AM ET
Data refreshes hourly during market hours. Next update: 2:57 AM
Data refreshes hourly during market hours. Next update: 2:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MIST showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Oliveto
SELL
36500 shares
2026-04-16
David Bharucha
SELL
12245 shares
2026-01-26
Jeffrey Edward Nelson
SELL
12245 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$446 | 60 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
